Literature DB >> 36125948

How we manage idiopathic multicentric Castleman disease.

Joshua D Brandstadter1, David C Fajgenbaum2.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 36125948      PMCID: PMC9584165     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  53 in total

1.  Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.

Authors:  Yujun Dong; Lu Zhang; Lin Nong; Lihong Wang; Zeyin Liang; Daobin Zhou; David C Fajgenbaum; Hanyun Ren; Jian Li
Journal:  Ann Hematol       Date:  2018-05-07       Impact factor: 3.673

Review 2.  A reference guide for management of Castleman disease.

Authors:  Kazuyuki Yoshizaki
Journal:  Rinsho Ketsueki       Date:  2017

3.  Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.

Authors:  Lu Zhang; Ai-Lin Zhao; Ming-Hui Duan; Zhi-Yuan Li; Xin-Xin Cao; Jun Feng; Dao-Bin Zhou; Ding-Rong Zhong; David C Fajgenbaum; Jian Li
Journal:  Blood       Date:  2019-02-13       Impact factor: 22.113

4.  Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.

Authors:  Enrique M Ocio; Fermin M Sanchez-Guijo; Maria Diez-Campelo; Cristina Castilla; Oscar J Blanco; Dolores Caballero; Jesus F San Miguel
Journal:  Am J Hematol       Date:  2005-04       Impact factor: 10.047

5.  Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; David Wu; Aaron Goodman; Raymond Wong; Amy Chadburn; Sunita Nasta; Gordan Srkalovic; Sudipto Mukherjee; Heather Leitch; Raj Jayanthan; Simone Ferrero; Yasuharu Sato; Steve Schey; Angela Dispenzieri; Eric Oksenhendler; Pier Luigi Zinzani; Mary Jo Lechowicz; Christian Hoffmann; Naveen Pemmaraju; Adam Bagg; Alexander Fossa; Megan S Lim; Frits van Rhee
Journal:  Am J Hematol       Date:  2020-09-25       Impact factor: 13.265

6.  IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report.

Authors:  Caroline Galeotti; Tu-Anh Tran; Stéphanie Franchi-Abella; Monique Fabre; Danièle Pariente; Isabelle Koné-Paut
Journal:  J Pediatr Hematol Oncol       Date:  2008-12       Impact factor: 1.289

7.  Increased mTOR activation in idiopathic multicentric Castleman disease.

Authors:  Daniel J Arenas; Katherine Floess; Dale Kobrin; Ruth-Anne Langan Pai; Maya B Srkalovic; Mark-Avery Tamakloe; Rozena Rasheed; Jasira Ziglar; Johnson Khor; Sophia A T Parente; Sheila K Pierson; Daniel Martinez; Gerald B Wertheim; Taku Kambayashi; Joseph Baur; David T Teachey; David C Fajgenbaum
Journal:  Blood       Date:  2020-05-07       Impact factor: 22.113

8.  Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.

Authors:  Hannah Lust; Shunyou Gong; Allison Remiker; Jenna Rossoff
Journal:  Pediatr Blood Cancer       Date:  2021-07-24       Impact factor: 3.167

9.  Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.

Authors:  Deanna E Morra; Sheila K Pierson; Dustin Shilling; Sepideh Nemat; Carlos Appiani; Mary Guilfoyle; Craig Tendler; Frits van Rhee; David C Fajgenbaum
Journal:  Br J Haematol       Date:  2018-09-11       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.